Active Surveillance
Active surveillance for favorable intermediate-risk prostate cancer involves a structured monitoring plan to track disease progression while avoiding or delaying definitive treatment. Patients typically undergo:
-PSA testing every 3–6 months
-Digital rectal exams (DRE) annually
-Multiparametric MRI as needed to assess suspicious areas or guide biopsy
-Prostate biopsy every 1–3 years, or sooner if PSA rises or MRI changes
This strategy is considered in older patients, those with significant comorbidities, or individuals who prioritize maintaining quality of life and want to avoid the potential side effects of surgery or radiation, such as urinary incontinence or sexual dysfunction.
Treatment Type: Other
Treatment Class: N/A
Treatment Modality: N/A
Review Summary
Based on the review, Active Surveillance appears to be an effective and appropriate management strategy for favorable intermediate-risk prostate cancer, especially for older patients or those with other health conditions. While there is a slightly higher risk of progression compared to low-risk disease, it allows patients to avoid immediate invasive treatments and provides close monitoring, potentially delaying more aggressive interventions for years.
This summary was generated by users' reviews
Breakdown by Category
Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.
Cost
Relief Speed
Side Effects
Treatment LineExplore various treatment options to empower yourself in making a well-informed choice.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
AI Summary of User Experiences
Not medical advice.
Based on the review, Active Surveillance appears to be an effective and appropriate management strategy for favorable intermediate-risk prostate cancer, especially for older patients or those with other health conditions. While there is a slightly higher risk of progression compared to low-risk disease, it allows patients to avoid immediate invasive treatments and provides close monitoring, potentially delaying more aggressive interventions for years.
Cost Relief Speed Side Effect Treatment LineNo reviews yet.
Be the first to share your experience with this treatment. Your insights help others make informed decisions about their care.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
Reviews
Filter by reviewer type Pro